CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Sante Manufacturing Inc., 2026-06-05
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
At a glance: FDA's Center for Drug Evaluation and Research (CDER) issued a Warning Letter to Sante Manufacturing Inc. on 2026-06-05 regarding CGMP/Finished Pharmaceuticals/Adulterated. The letter references 21 CFR 211.84(d)(1). The verbatim letter is published on fda.gov.
Argus analysis
Sante Manufacturing Inc. received a Warning Letter from FDA's Center for Drug Evaluation and Research (CDER), dated 2026-06-05, regarding CGMP/Finished Pharmaceuticals/Adulterated. The letter follows an FDA inspection and is classified by Argus HQ as high severity, consistent with Current Good Manufacturing Practice violations under 21 CFR Part 211 (drugs) or Part 600 (biologics).
The published letter cites 21 CFR 211.84(d)(1). Warning Letters citing these sections generally concern Current Good Manufacturing Practice violations under 21 CFR Part 211 (drugs) or Part 600 (biologics), typically covering component testing, cleaning validation, laboratory controls, or investigation of out-of-specification results. The full citation language and supporting observations are in the verbatim letter linked below — Argus HQ does not add citations beyond what FDA published.
FDA Warning Letters carry a 15-business-day response window for the recipient to detail corrective actions. Peer compliance teams in the same product category typically use a letter like this one as an external audit trigger, checking whether their own quality system has documented coverage for the cited sections and whether their CAPA log would withstand the same line of inspection questioning.
Severity context
High severity. Typically QSR / device CGMP, adulterated-drug, or significant labeling matters — usually drives a documented corrective and preventive action (CAPA) program.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Sante Manufacturing Inc. MARCS-CMS 724931 — June 05, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Electronic Mail - Return Receipt Requested Reference #: 320-26-94 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Mr. Wayne Kirby Recipient Title Owner Sante Manufacturing Inc. 516 John Street N 11A & 11B Aylmer ON N5H 2B8 Canada Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-94 June 5, 2026 Dear Mr. Kirby: Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our July 7, 2025, request and subsequent correspondence for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility, Sante Manufacturing Inc., FEI 3021535057, at 516 John Street N 11A & 11B Aylmer, Ontario, Canada. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)). Following review of records and other information provided pursuant to section 704(a)(4) of the FD&C Act, significant violations were observed including, but not limited to, the following: 1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)). Your firm manufactures OTC drug products such as (b)(4) . Based on the records and information you provided, you did not demonstrate that you adequately tested each shipment of each lot of incoming (b)(4) , a component at high risk for (b)(4) contamination, prior to its use in manufacturing. This includes testing of (b)(4) used in manufacturing drug products to determine its appropriate identity. Your firm also relied on the supplier’s certificate of analysis (COA) and accepted the (b)(4) component based on your supplier’s COA without establishing the reliability of your supplier’s test analyses at appropriate intervals. The use of ingredients contaminated with (b)(4) has resulted in various lethal poisoning incidents in humans worldwide. See (b)(4) to help you meet the CGMP requirements when manufacturing drugs containing ingredients at high-risk for (b)(4) contamination at (b)(4) . Without adequate te…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a CGMP — Current Good Manufacturing Practice warning letter?
- CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Sante Manufacturing Inc. had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Sante Manufacturing Inc. as of 2026-06-16. Argus ingests new FDA enforcement records daily.
- What FDA violations was Sante Manufacturing Inc. cited for?
- The FDA Warning Letter to Sante Manufacturing Inc. (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. $199/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Sante Manufacturing Inc., 2026-06-05. Digital Empire LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-sante-manufacturing-inc-2026-06-05-cgmp
"CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Sante Manufacturing Inc., 2026-06-05." Argus HQ Research, Digital Empire LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-sante-manufacturing-inc-2026-06-05-cgmp.
Argus HQ Research. "CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Sante Manufacturing Inc., 2026-06-05." Digital Empire LLC. Accessed July 13, 2026. https://argushq.ai/fda/warning-letter/fda-wl-sante-manufacturing-inc-2026-06-05-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_sante_manufacturing_inc_2026_06_05_cgmp_2026,
title = {CGMP/Finished Pharmaceuticals/Adulterated: FDA Warning Letter to Sante Manufacturing Inc., 2026-06-05},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-sante-manufacturing-inc-2026-06-05-cgmp},
note = {Accessed: July 13, 2026}
}